CAPS vs. BPTH, ADXS, SHPH, ZVSA, PTEIQ, PCSA, ASLN, PBLA, HEPA, and CWBR
Should you be buying Capstone stock or one of its competitors? The main competitors of Capstone include Bio-Path (BPTH), Ayala Pharmaceuticals (ADXS), Shuttle Pharmaceuticals (SHPH), ZyVersa Therapeutics (ZVSA), PolarityTE (PTEIQ), Processa Pharmaceuticals (PCSA), ASLAN Pharmaceuticals (ASLN), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), and CohBar (CWBR). These companies are all part of the "pharmaceutical products" industry.
Capstone vs.
Bio-Path (NASDAQ:BPTH) and Capstone (NASDAQ:CAPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
Bio-Path received 282 more outperform votes than Capstone when rated by MarketBeat users.
Bio-Path presently has a consensus price target of $20.00, indicating a potential upside of 12,095.12%. Given Bio-Path's stronger consensus rating and higher possible upside, equities analysts plainly believe Bio-Path is more favorable than Capstone.
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 2.5% of Capstone shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 42.8% of Capstone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Bio-Path had 1 more articles in the media than Capstone. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for Capstone. Capstone's average media sentiment score of 0.57 beat Bio-Path's score of 0.00 indicating that Capstone is being referred to more favorably in the news media.
Capstone's return on equity of 0.00% beat Bio-Path's return on equity.
Bio-Path has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Capstone has a beta of -0.82, indicating that its share price is 182% less volatile than the S&P 500.
Capstone has higher revenue and earnings than Bio-Path.
Summary
Bio-Path beats Capstone on 7 of the 12 factors compared between the two stocks.
Get Capstone News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capstone Competitors List
Related Companies and Tools
This page (NASDAQ:CAPS) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CAPS Stock Free CAPS Stock Alerts